CRL vs. INCY, MEDP, ICLR, IQV, RDY, PODD, SWAV, EXAS, RVTY, and DVA
Should you be buying Charles River Laboratories International stock or one of its competitors? The main competitors of Charles River Laboratories International include Incyte (INCY), Medpace (MEDP), ICON Public (ICLR), IQVIA (IQV), Dr. Reddy's Laboratories (RDY), Insulet (PODD), Shockwave Medical (SWAV), Exact Sciences (EXAS), Revvity (RVTY), and DaVita (DVA). These companies are all part of the "medical" sector.
Incyte (NASDAQ:INCY) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.
Incyte has a net margin of 16.17% compared to Incyte's net margin of 11.49%. Incyte's return on equity of 16.53% beat Charles River Laboratories International's return on equity.
Incyte currently has a consensus price target of $76.07, indicating a potential upside of 46.52%. Charles River Laboratories International has a consensus price target of $253.23, indicating a potential upside of 8.89%. Given Charles River Laboratories International's higher probable upside, equities research analysts plainly believe Incyte is more favorable than Charles River Laboratories International.
Incyte received 726 more outperform votes than Charles River Laboratories International when rated by MarketBeat users. Likewise, 73.61% of users gave Incyte an outperform vote while only 61.57% of users gave Charles River Laboratories International an outperform vote.
97.0% of Incyte shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 17.5% of Incyte shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Incyte has higher earnings, but lower revenue than Charles River Laboratories International. Incyte is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
In the previous week, Incyte had 10 more articles in the media than Charles River Laboratories International. MarketBeat recorded 13 mentions for Incyte and 3 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.87 beat Incyte's score of 0.67 indicating that Incyte is being referred to more favorably in the media.
Incyte has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
Summary
Incyte beats Charles River Laboratories International on 10 of the 17 factors compared between the two stocks.
Get Charles River Laboratories International News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charles River Laboratories International Competitors List
Related Companies and Tools
